Dr. Edwin P. Ewing, Jr. - http://phil.cdc.gov/phil/home.asp ID#: 70 US Department of Health and Human ServicesDuchenne Muscular DystrophyImlifidase enables gene therapy in Duchenne patients with AAV antibodiesInitial clinical data indicate that the recombinant cysteine protease imlifidase, developed by Hansa Biopharma AB, may significantly reduce levels of anti-AAV antibodies, potentially enabling adeno-associated … more ➔
Daniel Torok, Public domain, via Wikimedia CommonsUS Pharma Prices Trump sets 60-day deadline for US pharma price reductionsUS President Donald Trump has set a deadline in a letter to the CEOs of the 17 leading Big Pharma companies for the announced reduction of prescription drug prices. more ➔
Maxwell Hamilton - wikipedia.orgCOPDGSK licenses COPD blockbuster in US$12bn dealFollowing Merck Sharp & Dohme (MSD)’s US$10bn acquisition of Verona Pharma and its potential COPD blockbuster Ohtuvayre®, GlaxoSmithKline (GSK) has secured a US$12bn deal for another PDE3/PDE4 inhi … more ➔
Lift Biosciences LtdAllogeneic cancer immunotherapyLIfT BioSciences Ltd receives €12m for clinical translation of IMANsLIfT BioSciences Ltd, active in London, Galway and Houston, has been awarded a grant of €12m from the Disruptive Technologies Innovation Fund (DTIF) to support the clinical translation of its Immuno-Modulatory … more ➔
Celt Studio - adobe stock.comUS-EU trade conflictImport tariff of 15%: significant implications for pharmaceutical firmsIn the ongoing dispute over US import tariffs on European pharmaceuticals, the European Commission has acquiesced to a 15% tariff on EU pharmaceutical exports to the United States, as well as to the … more ➔
Bruno Coelho - stock.adobe.com Lung cancerBayer targets leading position in HER2-positive NSCLCThe potential blockbuster HER2 tyrosine kinase inhibitor sevabertinib, developed jointly by Bayer AG and the Broad Institute, is expected to be submitted for regulatory approval in China in Q3 2025 for … more ➔
Gerd Altmann/pixabay.comAcquisitionFrom Brisbane to London to Paris: Vicebio´s Sanofi dealFrom Brisbane to London to Paris: Australian vaccine innovation sparks US$1.15 billion deal with french Sanofi with an additional US$450 million tied to clinical milestones and underscoring a major commitment … more ➔
Abivax SAColitis UlcerosaAbivax soars 500% on TOP-Line dataIn a watershed moment for both patients and investors, shares in Abivax (Euronext Paris: ABVX / Nasdaq: ABVX) skyrocketed by a staggering 500% following the announcement of positive Phase 3 results from … more ➔
AstraZenecaAstraZenecaWestwards: AstraZeneca Shifts Gears with $50 Billion US InvestmentAstraZeneca announces a US$50 billion investment in the USA amid pharma’s transatlantic drift. Virgina is set to become the multi-billion-dollar drug manufacturing hub. more ➔
Carbios SAPET bio-recyclingCarbios is back with a partnership in the automotive tyre industryFrench CARBIOS SA signs strategic agreement with Indorama Ventures and Michelin amid broader company transition and sees itself back on track. Before opening of its production plant (delayed to later … more ➔
Dr. Edwin P. Ewing, Jr. - http://phil.cdc.gov/phil/home.asp ID#: 70 US Department of Health and Human Services
Daniel Torok, Public domain, via Wikimedia Commons
Maxwell Hamilton - wikipedia.org
Lift Biosciences Ltd
Celt Studio - adobe stock.com
Bruno Coelho - stock.adobe.com 
Gerd Altmann/pixabay.com
Abivax SA
AstraZeneca
Carbios SA